NEW YORK (GenomeWeb) – Backed by $8 million in funding, UK-based diagnostics firm Abcodia plans this year to roll out UK and US versions of its ROCA ovarian cancer test.

The company is aiming for a July launch in the UK and a Q4 launch in the US. According to Nadia Altomare, president of Abcodia's North American operations, the test in theUKwill initially be offered through private clinics on a "self-pay" basis, while in the US it will be sold as a laboratory-developed test offered through a CLIA laboratory Abcodia is currently in the process of establishing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.